Health Evidence Knowledge Accelerator (HEvKA) Daily Progress September 5, 2024
Brian Alper
Special participation opportunity:
We are creating a grant application titled “Setting Evidence-Based Medicine on Fast Healthcare Interoperability Resources (EBMonFHIR) as the data standard for biomedical research” for PAR-23-236 Early-stage Biomedical Data Repositories and Knowledgebases
You can help in 2 ways:
- Review the current version of the grant proposal and make suggestions (Research Strategy EBMonFHIR Knowledgebase.docx or any of the other pages listed in Associated Links on the project page for this proposal effort).
- Write a letter of support
- Thank you so far to Mike Hamidi (DataInterop LLC and HL7 Vulcan Accelerator), Ian Saldanha (Johns Hopkins Center for Clinical Trials and Evidence Syntehsis), Amy Price (Dartmouth Geisel School of Medicine), Gert van Valkenhoef (Cochrane), Claudia Bosio (Epistemonkios Foundation), Artur Novak (Evidence Prime), Kevin Hobbie (ICF International), Gustav Vella (Carelane), Allen Flynn (University of Michigan Medical School) for completing PDF letters of support.
------------------------------------------------------------------------------------------------------------
4 people (BA, CE , IK, RF) participated today in up to 2 active working group meetings.
The EBMonFHIR Implementation Guide Working Group (a CDS EBMonFHIR sub-WG) viewed a clean QA report for the EBMonFHIR Implementation Guide and modified the Other Profiles page to include the M11ResearchStudy Profile. We also reviewed the presentation in development for the Global Evidence Summit SPECIAL SESSION “Using technology to make the Evidence Ecosystem more efficient and effective: global collaborations for interoperability” and applied a feature enhancement to the FEvIR®: Recommendation Justification Builder/Viewer to improve screenshots of examples for this presentation.
The Computable EBM Tools Development Working Group reviewed the workflow for adapting a recommendation using the Computable Publishing®: Recommendation Authoring Tool to prepare for the Global Evidence Summit SPECIAL SESSION “Using technology to make the Evidence Ecosystem more efficient and effective: global collaborations for interoperability” and also reviewed the many updates to the FEvIR Platform over the past week:
- FEvIR Platform
- Release 0.254.0 (August 31, 2024) makes the editing interface faster and simpler by starting selected elements in collapsed mode unless the user clicks Edit to expand them for editing, including complex datatypes when editing extension values.
- Release 0.254.1 (September 1, 2024) fixes a bug to enable editing a referenced Resource upon initial creation from within a Resource Builder or Authoring Tool.
- Release 0.254.2 (September 4, 2024) increases the timeout period for submitting changes to Resources to the server.
- Release 0.254.3 (September 4, 2024) generates unique section codes on creation of new Composition sections without code values.
- Release 0.255.0 (September 4, 2024) adds a relatedArtifact entry to cloned resources referencing the derived-from Resource.
- Computable Publishing®: Baseline Measure Report Authoring Tool Release 0.12.0 (September 2, 2024) simplifies the “Add Default Sample Size” feature to automatically detect the Group.quantity value (N) for each referenced Group and present “Add (N) as Sample Size” for selection in creating Evidence Resources from the table; and simplifies the “Add Default Statistics/Units” feature to automatically detect the Evidence.statistic.statisticType and Evidence.statistic.quantity.unit values for any referenced noncomparative Evidence and present “Add Default Statistic Type {value} and Unites {value}” for selection in creating Evidence Resources from the table.
- Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter Release 4.13.0 (September 2, 2024) adjusts the EvidenceVariable Resources created to use the FHIR R6 pattern instead of the FHIR R5 pattern, including the baseline measures, outcome measures, and adverse effects measures.
- Computable Publishing®: Comparative Evidence Report Authoring Tool Release 0.32.0 (September 2, 2024) adds the ability to reorganize the sections and subsections of the ComparativeEvidenceReport Composition; and removes the “Create a Summary of Findings Report” button.
- Computable Publishing®: DOCX-to-JSON Sections Converter Release 0.3.1 (September 4, 2024) increases the timeout period for submitting changes to Resources to the server.
- Computable Publishing®: Outcome Measure Report Authoring Tool Release 0.4.0 (September 2, 2024) simplifies the “Add Default Sample Size” feature to automatically detect the Group.quantity value (N) for each referenced Group and present “Add (N) as Sample Size” for selection in creating Evidence Resources from the table; and simplifies the “Add Default Statistics/Units” feature to automatically detect the Evidence.statistic.statisticType and Evidence.statistic.quantity.unit values for any referenced noncomparative Evidence and present “Add Default Statistic Type {value} and Unites {value}” for selection in creating Evidence Resources from the table.
- Computable Publishing®: Participant Flow Report Authoring Tool Release 0.3.0 (September 2, 2024) simplifies the “Add Default Sample Size” feature to automatically detect the Group.quantity value (N) for each referenced Group and present “Add (N) as Sample Size” for selection in creating Evidence Resources from the table; and simplifies the “Add Default Statistics/Units” feature to automatically detect the Evidence.statistic.statisticType and Evidence.statistic.quantity.unit values for any referenced noncomparative Evidence and present “Add Default Statistic Type {value} and Unites {value}” for selection in creating Evidence Resources from the table.
- Computable Publishing®: Summary Of Findings Authoring Tool Release 0.29.0 (September 1, 2024) has SEVCO codes for risk difference, risk ratio, odds ratio, hazard ratio, prevalence ratio, incidence rate ratio, and count mapped to autogeneration of Summary of Net Effect Composition section Narrative values.
- FEvIR®: ActivityDefinition Builder/Viewer Release 0.20.0 (August 31, 2024) makes the editing interface faster and simpler by starting the following elements in collapsed mode unless the user clicks Edit to expand them for editing: text, code, timingTiming, timingAge, timingRange, timingDuration, asNeededCodeableConcept, location, participant, participant.typeReference, participant.role, participant.function, productReference, productCodeableConcept, quantity, dosage, bodySite, dynamicValue, subjectCodeableConcept, subjectReference.
- FEvIR®: Bundle Builder/Viewer Release 0.4.0 (August 31, 2024) makes the editing interface faster and simpler by starting the identifier element in collapsed mode unless the user clicks Edit to expand it for editing.
- FEvIR®: Composition Builder/Viewer Release 0.18.0 (August 31, 2024) makes the editing interface faster and simpler by starting some elements in collapsed mode unless the user clicks Edit to expand them for editing.
- FEvIR®: Evidence Builder/Viewer
- Release 0.36.0 (August 31, 2024) makes the editing interface faster and simpler by starting the following elements in collapsed mode unless the user clicks Edit to expand them for editing: description, assertion, text, variableDefinition, variableDefinition.description, variableDefinition.note, variableDefinition.roleSubtype, variableDefinition.observed, variableDefinition.intended, variableDefinition.directnessMatch, synthesisType, studyDesign, statistic, statistic.description, statistic.note, statistic.statisticType, statistic.category, statistic.quantity.
- Release 0.36.1 (September 1, 2024) makes the editing interface faster and simpler by starting the following elements in collapsed mode unless the user clicks Edit to expand them for editing: statistic.attributeEstimate, statistic.attributeEstimate.description, statistic.attributeEstimate.note, statistic.attributeEstimate.type, statistic.attributeEstimate.quantity, statistic.attributeEstimate.range, statistic.attributeEstimate.attributeEstimate, statistic.modelCharacteristic, statistic.modelCharacteristic.code, statistic.modelCharacteristic.valueCodeableConcept, statistic.modelCharacteristic.valueQuantity, statistic.modelCharacteristic.valueRange, statistic.modelCharacteristic.attribute. Evidence Builder also adjusts the data entry interface to statistic.modelCharacteristic to match the current FHIR specification.
- FEvIR®: EvidenceVariable Builder/Viewer Release 0.30.0 (September 1, 2024) makes the editing interface faster and simpler by starting the following elements in collapsed mode unless the user clicks Edit to expand them for editing: description, text, definition, category.
- FEvIR®: Group (Cohort Definition) Builder/Viewer Release 0.33.0 (September 1, 2024) makes the editing interface faster and simpler by starting the following elements in collapsed mode unless the user clicks Edit to expand them for editing: code, description, text, extension:characteristicExpression, managingEntity,
- FEvIR®: Library Builder/Viewer Release 0.3.0 (September 1, 2024) makes the editing interface faster and simpler by starting the following elements in collapsed mode unless the user clicks Edit to expand them for editing: text, description, type, subjectCodeableConcept, subjectReference, relatedArtifact, content.
- FEvIR®: List Builder/Viewer Release 0.5.0 (September 1, 2024) makes the editing interface faster and simpler by starting the following elements in collapsed mode unless the user clicks Edit to expand them for editing: text, code, subject, encounter, source, orderedBy, note, entry, entry.flag, entry.item.
- FEvIR®: Measure Builder/Viewer Release 0.4.0 (September 1, 2024) makes the editing interface faster and simpler by starting the following elements in collapsed mode unless the user clicks Edit to expand them for editing: text, description, disclaimer, scoring, scoringUnit, compositeScoring, riskAdjustment, rateAggregation, rationale, clinicalRecommendationStatement, improvementNotation, guidance, subjectCodeableConcept, subjectReference.
- FEvIR®: PlanDefinition Builder/Viewer Release 0.4.0 (September 1, 2024) makes the editing interface faster and simpler by starting the following elements in collapsed mode unless the user clicks Edit to expand them for editing: text, subjectCodeableConcept, subjectReference, asNeededCodeableConcept, type.
- FEvIR®: RAte of Dissemination Assessment Research (RADAR) ToolRelease 0.23.0 (September 3, 2024) supports Adjudication of Citing Article Ratings, and fixes a few bugs.
- FEvIR®: Recommendation Justification Builder/Viewer Release 0.29.0 (September 5, 2024) limits the autogeneration of the Summary to only include table rows where content is present.
- FEvIR®: ResearchStudy Builder/Viewer Release 0.13.1 (September 3, 2024) adjusts the intervention and comparator elements to become interventionGroup and comparatorGroup elements within the estimand extension for ResearchStudy.objective to be concordant with the developing EBMonFHIR Implementation Guide.
We are looking forward to many interactions in the Global Evidence Summit in Prague next week, including:
For the week of September 9 (no HEvKA meetings as many are in Global Evidence Summit in Prague):
|
Day/Time (Central European) |
Presentation/Meeting Type |
Presentation/Meeting Title |
|
Sep 10 Tuesday 11-12:30 am |
Special Session HALL D2 |
Using technology to make the Evidence Ecosystem more efficient and effective: global collaborations for interoperability |
|
Sep 11 Wednesday 7:30-8:30 am |
Working Group |
GINTech |
|
Sep 11 Wednesday 12:30-2 pm |
Poster |
P29 GINTech: Making Guidelines Computable |
|
Sep 12 Thursday 12:30-2 pm |
Poster |
P86 The GRADE Ontology Project |
|
Sep 13 Friday 10:04-10:11 am |
Oral Presentation |
How to Measure the Rate of Knowledge Transfer from Clinical Trials to Clinical Practice Guidance |
|
Sep 13 Friday 12-1:30 pm |
Poster |
P25 Scientific Evidence Code System (SEVCO): a common language for communicating evidence |
|
Sep 14 Saturday 9 am-5 pm |
GRADE Working Group |
agenda includes GRADE Ontology update |
Quote for thought: “Words can inspire, thoughts can provoke, but only action truly brings you closer to your dreams.” ―Brad Sugars
Brian S. Alper, MD, MSPH, FAAFP, FAMIA
CEO, Computable Publishing LLC
bal...@computablepublishing.com
Making Science Machine-Interpretable
http://computablepublishing.com
Lead, HEALTH EVIDENCE KNOWLEDGE ACCELERATOR
President, Scientific Knowledge Accelerator Foundation
Read about The Mission Change of a Lifetime
"It only takes a pebble to start an avalanche."
|
To get involved or stay informed: HEvKA Project Page on FEvIR Platform, HEvKA Project Page on HL7 Confluence, or join any of the groups that are now meeting in the following weekly schedule: Weekly Meeting Schedule and Link:
To join any of these meetings: ________________________________________________________________________________ Microsoft Teams meeting Join on your computer, mobile app or room device Click here to join the meeting *New Link as of January 2024! Meeting ID: 279 232 517 719 Download Teams | Join on the web Or call in (audio only) +1 929-346-7156,,35579956# United States, New York City Phone Conference ID: 355 799 56# Meeting support by ComputablePublishing.com
|
||||||||||||||||||||||||||||||||||||||||
|
|
The views and opinions included in this email belong to their author and do not necessarily mirror the views and opinions of the company. Our employees are obliged not to make any defamatory clauses, infringe, or authorize infringement of any legal right. Therefore, the company will not take any liability for such statements included in emails. In case of any damages or other liabilities arising, employees are fully responsible for the content of their emails.
Brian Alper
Special participation opportunity:
We are creating a grant application titled “Setting Evidence-Based Medicine on Fast Healthcare Interoperability Resources (EBMonFHIR) as the data standard for biomedical research” for PAR-23-236 Early-stage Biomedical Data Repositories and Knowledgebases
You can help in 2 ways:
- Review the current version of the grant proposal and make suggestions (Research Strategy EBMonFHIR Knowledgebase.docx or any of the other pages listed in Associated Links on the project page for this proposal effort).
- Write a letter of support
- Thank you so far to Mike Hamidi (DataInterop LLC and HL7 Vulcan Accelerator), Ian Saldanha (Johns Hopkins Center for Clinical Trials and Evidence Syntehsis), Amy Price (Dartmouth Geisel School of Medicine), Gert van Valkenhoef (Cochrane), Claudia Bosio (Epistemonkios Foundation), Artur Novak (Evidence Prime), Kevin Hobbie (ICF International), Gustav Vella (Carelane), Allen Flynn (University of Michigan Medical School), Eitan Agai (PICO Portal), and Janice Tufte (Hassanah Consulting) for completing PDF letters of support.
------------------------------------------------------------------------------------------------------------
8 people (AS, BA, HL, KW, MA, PW, SM, TD) participated today in up to 2 active working group meetings.
The Risk of Bias Terminology Working Group reviewed the feedback on multiple Rating of Bias Risk terms and revised the definition of rating of bias risk, re-opening it for vote. The 6 rating of bias risk terms open for voting are:
|
Term |
Definition |
Alternative Terms |
Comment for application |
|
The result of a qualitative assessment of the likelihood and potential impact of systematic distortion in research results. |
Bias is defined as a systematic distortion in research results (estimation of effect, association, or inference). Distortions in research results
means differences between the reported results (findings, conclusions, effect estimates) and the actuality (the truth, the estimand [the quantity targeted for estimation]). |
||
|
The result of a qualitative assessment that there is a low likelihood and potential impact of systematic distortion in research results. |
A 'low risk of bias' rating denotes a judgment that there are no serious concerns for bias. The 'potential impact of systematic distortion in research results' may include the impact on the clinical interpretation or conclusion of the study findings. |
||
|
The result of a qualitative assessment that there is some likelihood and potential impact of systematic distortion in research results, and this likelihood and potential impact is between low and high. |
|
The 'potential impact of systematic distortion in research results' may include the impact on the clinical interpretation or conclusion of the study findings. |
|
|
The result of a qualitative assessment that there is a high likelihood and potential impact of systematic distortion in research results. |
|
A 'high risk of bias' rating denotes a judgment that there are serious concerns for bias. The 'potential impact of systematic distortion in research results' may include the impact on the clinical interpretation or conclusion of the study findings. |
|
|
The result of a qualitative assessment that there is such as high likelihood and potential impact of systematic distortion in research results that the findings are not valid. |
|
The colloquial term 'fatal flaw' is sometimes used to report a critical risk of bias, signifying no further use of the study being assessed. |
|
|
There is insufficient information to make a qualitative assessment regarding the likelihood and potential impact of systematic distortion in research results. |
Unlike the terms
low risk of bias,
moderate risk of bias, and
high risk of bias, the term 'undetermined risk of bias' does not express a positive assertion of concern. The term 'unclear risk of bias' is not explicitly defined because it could be used to represent 'undetermined risk of bias' or
moderate risk of bias. |
To participate you can join the Scientific Evidence Code System (SEVCO) Expert Working Group at https://fevir.net/resources/Project/27845.
The GRADE Ontology Working Group reviewed a presentation for the GRADE Ontology Project Update to be presented at the GRADE Working Group meeting in Prague on September 14. Related meetings and presentations at the Global Evidence Summit include:
|
Day/Time (Central European) |
Presentation/Meeting Type |
Presentation/Meeting Title |
|
Sep 10 Tuesday 11-12:30 am |
Special Session HALL D2 |
Using technology to make the Evidence Ecosystem more efficient and effective: global collaborations for interoperability |
|
Sep 11 Wednesday 7:30-8:30 am |
Working Group |
GIN Tech |
|
Sep 11 Wednesday 12:30-2 pm |
Poster |
|
P29 GIN Tech: Making Guidelines Computable |
|
Sep 12 Thursday 12:30-2 pm |
Poster |
P86 The GRADE Ontology Project |
|
Sep 13 Friday 10:04-10:11 am |
Oral Presentation |
How to Measure the Rate of Knowledge Transfer from Clinical Trials to Clinical Practice Guidance |
|
Sep 13 Friday 12-1:30 pm |
Poster |
P25 Scientific Evidence Code System (SEVCO): a common language for communicating evidence |
|
Sep 14 Saturday 9 am-5 pm |
GRADE Working Group |
agenda includes GRADE Ontology update |
The terms Plausible opposing confounding and Large effect each received 6 affirmative and 2 negative votes. We reviewed the comments for Plausible opposing confounding and reset it for voting, and we are still open to comments on Large effect, so there are 2 terms open for vote:
|
Term |
Definition |
Alternative Terms |
Comment for application |
|
Confounding that may influence the effect in the opposite direction of the observed effect. |
|
Confounding is the distortion of an association between an exposure and an outcome by a third variable that is associated with both the exposure and the outcome. The effect of confounding may be suspected or observed.
|
|
|
An effect size that is substantially far from the null. |
|
If the effect is reported with a risk ratio, hazard ratio, or other relative measure for which a value of 1 means a null effect, then a 'large effect' may be considered for any value substantially greater than
1 (e.g. > 2) or any value substantially lesser than 1 (e.g. < 0.5). |
Please visit the term pages via the links in the table above and click the Comment button if you would like to share any comments that will be openly viewed by anyone visiting the page. You may also click the Vote button to anonymously register your agreement or disagreement with this term. If you vote ‘No’ you need to add a comment (along with your vote, not publicly shared with your name) explaining what change is needed to reach agreement.
To make voting on multiple terms easier you can use My Ballot at https://fevir.net/myballot -- You can go to My Ballot and mark any term with Yes if you approve, or with No (and add your comment to express what change is needed), or you can navigate to each term page to see additional detail.
Quote for thought: “Don’t stop when you are tired. Stop when you are done.” ―Unknown
Brian Alper
Thanks, Chuck.
HL7 supporting the use of FHIR as a standard for science data exchange in addition to health data exchange may be the difference for this NIH opportunity, and this NIH opportunity may be the key to establishing FHIR as the expected approach for research data sharing.
Brian
Brian S. Alper, MD, MSPH, FAAFP, FAMIA
CEO, Computable Publishing LLC
bal...@computablepublishing.com
Making Science Machine-Interpretable
http://computablepublishing.com
Lead, HEALTH EVIDENCE KNOWLEDGE ACCELERATOR
President, Scientific Knowledge Accelerator Foundation
Read about The Mission Change of a Lifetime
"It only takes a pebble to start an avalanche."
From: Charles Jaffe, MD <cja...@hl7.org>
Sent: Friday, September 6, 2024 7:16 PM
To: Brian Alper <bal...@computablepublishing.com>; Joanne Dehnbostel <jdehn...@computablepublishing.com>; Health Evidence Knowledge Accelerator (HEvKA) <HE...@computablepublishing.com>
Cc: Karen Van Hentenryck <kare...@hl7.org>
Subject: Re: Health Evidence Knowledge Accelerator (HEvKA) Daily Progress September 6, 2024
Brian,
Thanks for the reminder. I apologize for the delay, but I needed approval from the Executive Committee. I hope to obtain that on Monday.
At the moment, I am flying home from Boston, but always feel free to call me
Very best,
Chuck
Iorio, Alfonso
Fyi
All the best
Iorio, Alfonso
From:
Brian Alper <bal...@computablepublishing.com>
Date: Saturday, September 7, 2024 at 6:29
AM
To: Charles Jaffe, MD (HL7) <cja...@hl7.org>, Joanne Dehnbostel <jdehn...@computablepublishing.com>, Health Evidence Knowledge Accelerator (HEvKA) <HE...@computablepublishing.com>
Cc: Karen Van Hentenryck <kare...@hl7.org>
Subject: RE: Health Evidence Knowledge Accelerator (HEvKA) Daily Progress September 6, 2024
|
Caution: External email. |
Brian Alper
Special participation opportunity:
We are creating a grant application titled “Setting Evidence-Based Medicine on Fast Healthcare Interoperability Resources (EBMonFHIR) as the data standard for biomedical research” for PAR-23-236 Early-stage Biomedical Data Repositories and Knowledgebases
You can help in 2 ways:
- Review the current version of the grant proposal and make suggestions (Research Strategy EBMonFHIR Knowledgebase.docx or any of the other pages listed in Associated Links on the project page for this proposal effort).
- Write a letter of support
- Thank you so far to Mike Hamidi (DataInterop LLC and HL7 Vulcan Accelerator), Ian Saldanha (Johns Hopkins Center for Clinical Trials and Evidence Syntehsis), Amy Price (Dartmouth Geisel School of Medicine), Gert van Valkenhoef (Cochrane), Claudia Bosio (Epistemonkios Foundation), Artur Novak (Evidence Prime), Kevin Hobbie (ICF International), Gustav Vella (Carelane), Allen Flynn (University of Michigan Medical School), Eitan Agai (PICO Portal), Janice Tufte (Hassanah Consulting), Alfonso Iorio (McMaster University Department of Health Research Methods, Evidence, and Impact), and Jens Jap (MYCENAEAN Limited) for completing PDF letters of support.
------------------------------------------------------------------------------------------------------------
No HEvKA meetings today (or this week) as we are participating in the Global Evidence Summit:
|
Day/Time (Central European) |
Presentation/Meeting Type |
Presentation/Meeting Title |
|
Sep 10 Tuesday 11-12:30 am |
Special Session HALL D2 |
Using technology to make the Evidence Ecosystem more efficient and effective: global collaborations for interoperability |
|
Sep 11 Wednesday 7:30-8:30 am |
Working Group |
GIN Tech |
|
Sep 11 Wednesday 12:30-2 pm |
Poster |
P29 GIN Tech: Making Guidelines Computable |
|
Sep 12 Thursday 12:30-2 pm |
Poster |
P86 The GRADE Ontology Project |
|
Sep 13 Friday 10:04-10:11 am |
Oral Presentation |
How to Measure the Rate of Knowledge Transfer from Clinical Trials to Clinical Practice Guidance |
|
Sep 13 Friday 12-1:30 pm |
Poster |
P25 Scientific Evidence Code System (SEVCO): a common language for communicating evidence |
|
Sep 14 Saturday 9 am-5 pm |
GRADE Working Group |
agenda includes GRADE Ontology update |
Recent Releases on the FEvIR Platform:
- FEvIR Platform Release 0.256.0 (September 9, 2024) replaces the “Rate” button with a “RoBAT” button for Composition Resources to provide access to the Computable Publishing®: Risk of Bias Assessment Tool.
- Computable Publishing®: GRADEpro-to-FEvIR Converter
- Release 0.7.0 (September 7, 2024) supports conversion of evidence summaries from single studies in addition to evidence summaries from pooled synthesis.
- Release 0.8.0 (September 9, 2024) supports conversion of evidence summaries for more codes in the GRADEpro data, and adds a statistic.category ‘for control risk VALUE’ when there are multiple absolute effect estimates.
Quote for thought: “Only those who will risk going too far can possibly find out how far one can go.” ―T.S. Eliot
Brian Alper
Special participation opportunity:
We are creating a grant application titled “Setting Evidence-Based Medicine on Fast Healthcare Interoperability Resources (EBMonFHIR) as the data standard for biomedical research” for PAR-23-236 Early-stage Biomedical Data Repositories and Knowledgebases
You can help in 2 ways:
- Review the current version of the grant proposal and make suggestions (Research Strategy EBMonFHIR Knowledgebase.docx or any of the other pages listed in Associated Links on the project page for this proposal effort).
- Write a letter of support – please complete by September 17.
- Thank you so far to Mike Hamidi (DataInterop LLC and HL7 Vulcan Accelerator), Ian Saldanha (Johns Hopkins Center for Clinical Trials and Evidence Syntehsis), Amy Price (Dartmouth Geisel School of Medicine), Gert van Valkenhoef (Cochrane), Claudia Bosio (Epistemonkios Foundation), Artur Novak (Evidence Prime), Kevin Hobbie (ICF International), Gustav Vella (Carelane), Allen Flynn (University of Michigan Medical School), Eitan Agai (PICO Portal), Janice Tufte (Hassanah Consulting), Alfonso Iorio (McMaster University Department of Health Research Methods, Evidence, and Impact), Jens Jap (MYCENAEAN Limited), Betsy Jones, Julia Colpitts, and Marty Mayer (EBSCO Clinical Decisions), and Chuck Jaffe and Julia Skapik (HL7) for completing PDF letters of support.
------------------------------------------------------------------------------------------------------------
No HEvKA meetings today (or this week) as we are participating in the Global Evidence Summit:
|
Day/Time (Central European) |
Presentation/Meeting Type |
Presentation/Meeting Title |
|
Sep 10 Tuesday 11-12:30 am |
Special Session HALL D2 |
Using technology to make the Evidence Ecosystem more efficient and effective: global collaborations for interoperability |
|
Sep 11 Wednesday 7:30-8:30 am |
|
Working Group HALL D3 |
GIN Tech |
|
Sep 11 Wednesday 12:30-2 pm |
Poster P29 |
GIN Tech: Making Guidelines Computable |
|
Sep 12 Thursday 12:30-2 pm |
Poster P86 |
The GRADE Ontology Project |
|
Sep 13 Friday 10:04-10:11 am |
Oral Presentation |
How to Measure the Rate of Knowledge Transfer from Clinical Trials to Clinical Practice Guidance |
|
Sep 13 Friday 12-1:30 pm |
Poster P25 |
Scientific Evidence Code System (SEVCO): a common language for communicating evidence |
|
Sep 14 Saturday 9 am-5 pm |
GRADE Working Group |
agenda includes GRADE Ontology update |
The Special Session “Using technology to make the Evidence Ecosystem more efficient and effective: global collaborations for interoperability” was well attended and well received. The room capacity was limited to 100 and we learned that additional people were interested but not allowed in for fire safety reasons. Presentation slides for this 90-minute session area available here.
Personally, I was honored unexpectedly at the Annual General Meeting of the Guidelines International Network to be named a Fellow of the Guidelines International Network. (And I thought I was done putting letters after my name.)
Quote for thought: “If we were meant to stay in one place, we’d have roots instead of feet.” –Rachel Wolchin
Brian S. Alper, MD, MSPH, FAAFP, FAMIA, FGIN
CEO, Computable Publishing LLC
bal...@computablepublishing.com
Making Science Machine-Interpretable
http://computablepublishing.com
Lead, HEALTH EVIDENCE KNOWLEDGE ACCELERATOR
President, Scientific Knowledge Accelerator Foundation
Read about The Mission Change of a Lifetime
"It only takes a pebble to start an avalanche."
Brian Alper
The GIN Tech meeting included participants from China, Denmark, Finland, Japan, the Netherlands, Norway, Sweden, and the United States.
Feedback from implementers revealed that the ComparativeEvidenceReport Profile in the EBMonFHIR Implementation Guide, which supports use of the same population group, intervention group, and comparator group for all outcomes works for a single research study but not for a synthesis of studies where the observed groups are different for each outcome. We drafted a ComparativeEvidenceSynthesisReport Profile to support this need for evidence syntheses.
Quote for thought: “Don’t tell people about your dreams. Show them your dreams.” ―Unknown
Brian Alper
Special participation opportunity:
We are creating a grant application titled “Setting Evidence-Based Medicine on Fast Healthcare Interoperability Resources (EBMonFHIR) as the data standard for biomedical research” for PAR-23-236 Early-stage Biomedical Data Repositories and Knowledgebases
You can help in 2 ways:
- Review the current version of the grant proposal and make suggestions (Research Strategy EBMonFHIR Knowledgebase.docx or any of the other pages listed in Associated Links on the project page for this proposal effort).
- Write a letter of support – please complete by September 17.
- Thank you so far to Mike Hamidi (DataInterop LLC and HL7 Vulcan Accelerator), Ian Saldanha (Johns Hopkins Center for Clinical Trials and Evidence Syntehsis), Amy Price (Dartmouth Geisel School of Medicine), Gert van Valkenhoef (Cochrane), Claudia Bosio (Epistemonkios Foundation), Artur Novak (Evidence Prime), Kevin Hobbie (ICF International), Gustav Vella (Carelane), Allen Flynn (University of Michigan Medical School), Eitan Agai (PICO Portal), Janice Tufte (Hassanah Consulting), Alfonso Iorio (McMaster University Department of Health Research Methods, Evidence, and Impact), Jens Jap (MYCENAEAN Limited), Betsy Jones, Julia Colpitts, and Marty Mayer (EBSCO Clinical Decisions), Chuck Jaffe and Julia Skapik (HL7), and Etienne Ngeh (Guidelines International Network Africa Regional Community) for completing PDF letters of support.
As noted yesterday, feedback from implementers revealed that the ComparativeEvidenceReport Profile in the EBMonFHIR Implementation Guide, which supports use of the same population group, intervention group, and comparator group for all outcomes works for a single research study but not for a synthesis of studies where the observed groups are different for each outcome. We drafted a ComparativeEvidenceSynthesisReport Profile to support this need for evidence syntheses, and after debugging it is now available in the EBMonFHIR Implementation Guide. Next steps will be to modify our MAGICapp and GRADEpro converter tools to use this new Profile and learn how to improve the Profile in the process.
Quote for thought: “I’m not a product of my circumstances. I am a product of my decisions.” ―Stephen Covey
Brian Alper
Special participation opportunity:
We are creating a grant application titled “Setting Evidence-Based Medicine on Fast Healthcare Interoperability Resources (EBMonFHIR) as the data standard for biomedical research” for PAR-23-236 Early-stage Biomedical Data Repositories and Knowledgebases
You can help in 2 ways:
- Review the current version of the grant proposal and make suggestions (Research Strategy EBMonFHIR Knowledgebase.docx or any of the other pages listed in Associated Links on the project page for this proposal effort).
- Write a letter of support – please complete by September 17.
- Thank you so far to Mike Hamidi (DataInterop LLC and HL7 Vulcan Accelerator), Ian Saldanha (Johns Hopkins Center for Clinical Trials and Evidence Syntehsis), Amy Price (Dartmouth Geisel School of Medicine), Gert van Valkenhoef (Cochrane), Claudia Bosio (Epistemonkios Foundation), Artur Novak (Evidence Prime), Kevin Hobbie (ICF International), Gustav Vella (Carelane), Allen Flynn (University of Michigan Medical School), Eitan Agai (PICO Portal), Janice Tufte (Hassanah Consulting), Alfonso Iorio (McMaster University Department of Health Research Methods, Evidence, and Impact), Jens Jap (MYCENAEAN Limited), Betsy Jones, Julia Colpitts, and Marty Mayer (EBSCO Clinical Decisions), Chuck Jaffe and Julia Skapik (HL7), Etienne Ngeh (Guidelines International Network Africa Regional Community), and Kylie Porritt (JBI) for completing PDF letters of support.
In a subsequent update and/or on the HEvKA project page at https://fevir.net/resources/Project/29272 -- we will share links to the presentations noted above.
Quote for thought: “When I hear somebody sigh, ‘Life is hard,’ I am always tempted to ask, ‘Compared to what?'” —Sydney J. Harris
Brian Alper
No HEvKA meetings today (or Tuesday through Thursday) as we are participating in the HL7 Working Group Meeting.
In the HL7 FHIR Connectathon Evidence-Based Medicine (EBM) Track, we summarized the weekend with the following:
- What was the track trying to achieve?
- introduction to new participants
- modeling for EBMonFHIR Implementation Guide
- tooling revisions for FEvIR Platform
- List of participants (with logos if you have time and energy)
- Brian S. Alper, Computable Publishing LLC
- Khalid Shahin, Computable Publishing LLC
- Esmeralda Bolanos, Oracle
- Zameer Sura, Oracle
- Kota Torikai, University Hospital in Maebashi Japan
- Sophie Klopfenstein, Berlin Institute of Health at Charite
- Notable achievements
- introduction of EBMonFHIR to 3 new participants
- Modeling of new DataDictionary Resource to use for a data dictionary (the keys for sharing research datasets)
- FEvIR Platform refactoring to support section-level navigation, viewing and editing for Composition Resources
- Screenshots and/or links to further information
Quote for thought: “We just agreed in a group delusion that it works” —out-of-context statement uttered at a standards development work group meeting
Brian Alper
No HEvKA meetings today (or tomorrow or Thursday) as we are participating in the HL7 Working Group Meeting.
A presentation on What is Evidence Based Medicine on FHIR? was very well received.
To support a common approach to data dictionaries to support sharing the ‘code key’ when sharing research datasets, we will propose tomorrow to the HL7 Biomedical Research and Regulation (BRR) Work Group to create a FHIR DataDictionary Resource. First draft model available at EBMonFHIR IG DataDictionary Profile.
Releases today on the FEvIR Platform:
- FEvIR Platform Release 0.258.0 (September 24, 2024) standardizes processing for creating, reading, and updating FHIR Resources.
- FEvIR®: Composition Builder/Viewer Release 0.21.0 (September 24, 2024) includes a Section Detail tab with a user-friendly interface to support editing of section content for the selected section.
- Computable Publishing®: M11 Report Authoring Tool Release 0.19.0 (September 24, 2024) adds Reorganize Sections button to the Text View and supports Profile-specific editing features in Section Detail editing for the Oversight, Supporting Details, Glossary, and References sections.
Quote for thought: “If you're doing something the same way you have been doing it for ten years, the chances are you are doing it wrong.” — Charles F. Kettering.
Brian Alper
No HEvKA meetings today (or tomorrow) as we are participating in the HL7 Working Group Meeting.
Today’s events are mostly captured in the ‘Update of EBMonFHIR activities’ that is transiently listed in the FHIR Trackers across EBMonFHIR/HEvKA efforts, followed by a ‘to do list’ for the EBMonFHIR project.
Quote for thought: “Quality is not an extension.” — Floyd Eisenberg, MD, MPH, FACP